SCHEMBL193426

SCHEMBL193426

CCCCC1(O)C=CC=CC1C=O

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 2/20 0.35
DNTT P04053 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29210938 0.94 POLA1 (0.43) POLA1DNTTPOLB
SCHEMBL3431677 0.90
SCHEMBL15921915 0.82
SCHEMBL20994065 0.77
SCHEMBL2975191 0.75 POLA1 (0.39) POLA1DNTTPOLB
SCHEMBL9423932 0.73 POLA1 (0.30) POLA1
SCHEMBL39811 0.73 POLA1 (0.38) POLA1DNTTPOLB
SCHEMBL23853020 0.73
SCHEMBL6276544 0.69 POLA1 (0.47) POLA1DNTTPOLB
SCHEMBL3650233 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384013-A Method for generating hydroxyl radical by utilizing Schiff base cerium complex 上海致同建设工程科技有限公司 2024-01-12 CN disclosed
EP-2912016-A1 NOVEL CATALYST COMPOSITIONS AND METHODS OF MAKING AND USING SAME Chevron Phillips Chemical Company LP (US) 2015-09-02 EP disclosed
WO-2014066602-A1 NOVEL CATALYST COMPOSITIONS AND METHODS OF MAKING AND USING SAME CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2014-05-01 WO disclosed
EP-2401074-A1 ALKOXYLATION PROCESSES AND CATALYSTS THEREFOR Dow Global Technologies LLC (US) 2012-01-04 EP disclosed
US-20070134338-A1 Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology KANSAS UNIVERSITY OF, THE 2007-06-14 US disclosed
WO-2006133354-A2 METHODS FOR PRODUCING NANOPARTICULATE METAL COMPLEXES AND ALTERING NANOPARTICLE MORPHOLOGY UNIVERSITY OF KANSAS (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070134338-A1 Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology NCSTN, NCLN, NCDN POLA1 2289/4885DNTT 2052/4885POLB 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.